(-)-isoproterenol | 42173-39-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (-)-isoproterenol
• 英文别名: Iso；(R)-1-(3,4-dihydroxy-phenyl)-2-dimethylamino-ethanol；(R)-1-(3,4-Dihydroxy-phenyl)-2-dimethylamino-aethanol；4-[(1R)-2-(dimethylamino)-1-hydroxyethyl]benzene-1,2-diol
• CAS: 42173-39-7
• 化学式: C₁₀H₁₅NO₃
• 分子量: 197.234
• InChiKey: RLATYNCITHOLTJ-JTQLQIEISA-N

物化性质

• 沸点：
  393.4±42.0 °C(Predicted)
• 密度：
  1.251±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  63.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Α-二甲氨基-3',4'-二羟基苯乙酮盐酸盐 在 乙醇 、 D-酒石酸 、 铂 作用下， 生成 (-)-isoproterenol
  参考文献：
  名称：

  La Manna; Campiglio, Farmaco, Edizione Scientifica, 1959, vol. 14, p. 317,320

  摘要：

  DOI：

文献信息

• Stable-Isotope Dimethylation Labeling Combined with LC−ESI MS for Quantification of Amine-Containing Metabolites in Biological Samples
  作者：Kevin Guo、Chengjie Ji、Liang Li

  DOI：10.1021/ac0704356

  日期：2007.11.1

  was found that deuterium labeling causes an isotope effect on the elution of labeled amines on RPLC but has no effect on HILIC LC. However, 13C-dimethylation does not show any isotope effect on either RPLC or HILIC LC, indicating that 13C-labeling is a preferred approach for relative quantification of amine-containing metabolites in different samples. The isotopically labeled 35 amine-containing analogues

  与复杂的生物样品中的代谢物谱分析相关的挑战之一是生成有关目标代谢物的定量信息。在这项工作中，提出了针对性的代谢组学分析策略，用于定量含胺代谢物。使用二甲基化反应将稳定的同位素标记引入到含胺的代谢物上，然后进行LC-ESI MS分析。该标记反应采用一种常见的试剂甲醛，通过还原胺化来全局标记胺基。通过LC-ESI MS分析20种氨基酸和15种胺后，研究了该策略的性能。结果表明，标记化学反应简单，快速（<10分钟反应时间），特异性强，在温和的反应条件下产率高。考察了标记胺对反相（RP）和亲水相互作用（HILIC）LC分离的同位素效应问题。发现氘标记对RPLC上标记胺的洗脱产生同位素影响，但对HILIC LC没有影响。但是，13C-二甲基化对RPLC或HILIC LC均未显示任何同位素作用，表明13C-标记是对不同样品中含胺代谢物进行相对定量的优选方法。发现同位素标记的35种含胺类似物是稳定的，并
• MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES
  申请人：DH TECHNOLOGIES DEVELOPMENT PTE. LTD.

  公开号：US20160305969A1

  公开（公告）日：2016-10-20

  A method is described for mass spectrometric analysis, detection and quantification of catecholamines. The methods can comprise reacting the catecholamines with a 4-aminoantippyrine reagent and detecting and/or quantifying the adduct produced by the reaction. The methods can also allow for multiplexing. Compounds formed by the reactions are also provided.

  描述了一种用于质谱分析、检测和定量儿茶酚胺的方法。该方法可以包括将儿茶酚胺与4-氨基安替比林试剂反应，并检测和/或定量由反应产生的加合物。该方法还可以实现多重复合。还提供了反应产生的化合物。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods and compositions for treating conditions associated with an abnormal inflammatory response
  申请人：First Wave Bio, Inc.

  公开号：US10772854B2

  公开（公告）日：2020-09-15

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods of treatment
  申请人：First Wave Bio, Inc.

  公开号：US10980756B1

  公开（公告）日：2021-04-20

  This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity (e.g., a chemical purity of greater than about 99.0%) or a particular particle size (e.g., a particular particle size distribution and/or a particular particle size range and/or a specific surface area range). In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for administration to the GI tract (e.g., orally or rectally such as via enema)).

  本公开的化合物和组合物适用于治疗有需要的受试者的冠状病毒感染的方法（例如，适用于治疗COVID-19的方法）。这些方法包括向受试者施用烟酰胺化合物（或其药学上可接受的盐和/或共晶体，例如烟酰胺）。在一些实施方案中，烟酰胺化合物具有一种或多种特性，包括但不限于：特定的纯度（例如化学纯度大于约99.0%）或特定的粒度（例如特定的粒度分布和/或特定的粒度范围和/或比表面积范围）。在一个方面，本文所述的烟酰胺化合物（如烟酰胺）可以构成组合物、剂型（如单位剂型）等的一部分，适合呼吸道给药（如通过吸入和/或鼻内给药）。在另一方面，本文所述的烟酰胺化合物（如烟酰胺）可构成组合物、剂型（如单位剂型）等的一部分，适合于消化道给药（如口服或直肠给药，如通过灌肠））。